» Articles » PMID: 23592565

Impact of Statin Use on Lipid Levels in Statin-naive Patients with Rheumatoid Arthritis Versus Non-rheumatoid Arthritis Subjects: Results from a Population-based Study

Overview
Specialty Rheumatology
Date 2013 Apr 18
PMID 23592565
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine lipid profiles among statin-naive patients with rheumatoid arthritis (RA) and those without RA before and after the initiation of statins.

Methods: Information regarding lipid measures and statin use was gathered in a population-based incident cohort of patients with RA (1987 American College of Rheumatology criteria first met between January 1, 1988 and January 1, 2008) and in a cohort of non-RA subjects from the same underlying population. Only patients with no prior history of statin use were included.

Results: The study included 161 patients with RA (mean age 56.3 years, 57% female) and 221 non-RA subjects (mean age 56.0 years, 66% female). Prior to the start of statins, the levels of total cholesterol and low-density lipoprotein (LDL) cholesterol were lower in the RA versus the non-RA cohort (P < 0.001 and P = 0.003, respectively). The absolute and percentage change in LDL cholesterol after at least 90 days of statin use tended to be smaller in the RA versus the non-RA cohort (P = 0.03 and P = 0.09, respectively). After at least 90 days of statin use, patients with RA were less likely to achieve therapeutic goals for LDL cholesterol than the non-RA subjects (P = 0.046). Increased erythrocyte sedimentation rate (ESR) at baseline (odds ratio 0.47, 95% confidence interval 0.26-0.85) was associated with lower likelihood of achieving therapeutic LDL goals.

Conclusion: Patients with RA had lower total cholesterol and LDL cholesterol levels before statin initiation and lower likelihood of achieving therapeutic LDL goals following statin use than the non-RA subjects. Some RA disease characteristics, in particular ESR at baseline, may have an adverse impact on achieving therapeutic LDL goals.

Citing Articles

Atherosclerotic vascular disease in the autoimmune rheumatologic woman.

Kurmann R, Mankad R Clin Cardiol. 2018; 41(2):258-263.

PMID: 29480591 PMC: 6489857. DOI: 10.1002/clc.22916.


The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis.

Soulaidopoulos S, Nikiphorou E, Dimitroulas T, Kitas G Front Med (Lausanne). 2018; 5:24.

PMID: 29473041 PMC: 5809441. DOI: 10.3389/fmed.2018.00024.


Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients.

Restrepo J, del Rincon I, Molina E, Battafarano D, Escalante A J Clin Rheumatol. 2017; 23(3):144-148.

PMID: 28277344 PMC: 5364043. DOI: 10.1097/RHU.0000000000000502.


Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment.

Lazurova I, Tomas L Clin Rev Allergy Immunol. 2016; 52(3):323-332.

PMID: 27342458 DOI: 10.1007/s12016-016-8566-3.


Lipid and Metabolic Changes in Rheumatoid Arthritis.

McGrath C, Young S Curr Rheumatol Rep. 2015; 17(9):57.

PMID: 26210510 DOI: 10.1007/s11926-015-0534-z.


References
1.
Kremers H, Myasoedova E, Crowson C, Savova G, Gabriel S, Matteson E . The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases. Rheumatology (Oxford). 2010; 50(1):6-15. PMC: 3716332. DOI: 10.1093/rheumatology/keq199. View

2.
Semb A, Holme I, Kvien T, Pedersen T . Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford). 2010; 50(2):324-9. DOI: 10.1093/rheumatology/keq295. View

3.
PEARSON T, Laurora I, Chu H, Kafonek S . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4):459-67. DOI: 10.1001/archinte.160.4.459. View

4.
Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

5.
Melton 3rd L . History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71(3):266-74. DOI: 10.4065/71.3.266. View